Sector News

Amgen's global footprint grows with Japan a focal point

August 1, 2016
Life sciences

Amgen highlighted its increasingly global reach on the second quarter earnings call with Bob Bradway, chairman and CEO, in particular citing a recent deal with Daiichi Sankyo in Japan as key for biosimilar sales.

“With an expected 80 new launches across countries and products this year, and the recent re-acquisition of rights to many of our existing products outside the United States, we’re meaningfully expanding our global footprint,” Bradway told analysts on the July 27 earnings call.

“To that end, we recently announced that we had partnered with Daiichi Sankyo in an effort to bring Amgen biosimilars to the Japanese market.”

That deal will see Daiichi Sankyo market and sell 9 products, including approved and late-stage development biosimilars of adalimumab, bevacizumab (Avastin) and trastuzumab (Herceptin), though no mention was made at the time of the deal or on the call about rituximab (Rituxan), cetuximab (Erbitux) and infliximab (Remicade) that are part of Amgen’s biosimilar efforts.

Amgen has extensive dealings with Japanese firms and has relied on a mixture of research and sales and marketing help, as well as its own efforts. In June, for example, Osaka-based Takeda Pharmaceutical returned Japan rights for Amgen oncology candidates fulranumab (AMG-403) and trebananib (AMG-386).

But the California biotech does not break out the market by sales, with Tony Hooper, head of Global Commercial Operations, instead giving an overall figure outside the U.S. as international sales that rose 3% in the second quarter, “or 5% year over year, excluding the impact of foreign exchange. Europe was a strong contributor, with 11% unit growth.”

By EJ Lane

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”